lipolysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-24 and is reviewed periodically as new material appears.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Aeromonas infection African tick bite fever American tick bite fever (Rickettsia parkeri infection) Arcanobacterium haemolyticum infection Bacillary angiomatosis Bejel (endemic syphilis) Blastomycosis-like pyoderma (pyoderma vegetans) Blistering distal dactylitis Botryomycosis Brill–Zinsser disease Brucellosis (Bang's disease, Malta fever, undulant fever) Bubonic plague Bullous impetigo Cat scratch disease (cat scratch fever, English–Wear infection, inoculation lymphoreticulosis, subacute regional lymphadenitis) Cellulitis Chancre Chancroid (soft chancre, ulcus molle) Chlamydial infection Chronic lymphangitis Chronic recurrent erysipelas Chronic undermining burrowing ulcers (Meleney gangrene) Chromobacteriosis infection Condylomata lata Cutaneous actinomycosis Cutaneous anthrax infection Cutaneous C.
Erectile dysfunction (ED), also referred to as impotence, is a form of sexual dysfunction in males characterized by the persistent or recurring inability to achieve or maintain a penile erection with sufficient rigidity and duration for satisfactory sexual activity. It is the most common sexual problem in males and can cause psychological distress due to its impact on self-image and sexual relationships. The term erectile dysfunction does not encompass other erection-related disorders, such as priapism. The majority of ED cases are attributed to physical risk factors and predictive factors. These factors can be categorized as vascular, neurological, local penile, hormonal, and drug-induced. Notable predictors of ED include aging, cardiovascular disease, diabetes mellitus, high blood pressure, obesity, abnormal lipid levels in the blood, hypogonadism, smoking, depression, and medication use. Approximately 10% of cases are linked to psychosocial factors, encompassing conditions such as depression, stress, and problems within relationships. ED is reported in 18% of males aged 50 to 59 years, and 37% in males aged 70 to 75. Treatment of ED encompasses addressing the underlying causes, lifestyle modification, and addressing psychosocial issues. In many instances, medication-based therapies are used, specifically PDE5 inhibitors such as sildenafil. These drugs function by dilating blood vessels, facilitating increased blood flow into the spongy tissue of the penis, analogous to opening a valve wider to enhance water flow in a fire hose.
Leucine-rich repeats and death domain containing, also known as LRDD or p53-induced protein with a death domain (PIDD), is a protein which in humans is encoded by the LRDD gene. The leucine-rich repeat (LRR), first identified by Patthy, is a domain involved in protein-protein interactions and is present in numerous proteins that serve a variety of cellular roles. Leucine-rich repeats (LRR) proteins in eukaryotic cells are found in the nucleus, cytoplasm, extracellular matrix and plasma membrane.
== Function == A nerve conveys information in the form of electrochemical impulses (as nerve impulses known as action potentials) carried by the individual neurons that make up the nerve. These impulses are extremely fast, with some myelinated neurons conducting at speeds up to 120 m/s. The impulses travel from one neuron to another by crossing a synapse, where the message is converted from electrical to chemical and then back to electrical.
Sources: en.wikipedia.org
== History == Medtronic replaced the Paradigm insulin pump with its new pump platform, the 640G, internationally in 2015. Its successive pumps have used the same form factor. In the United States, the 670G was released in 2017. It used an algorithm called SmartGuard to adjust the basal insulin rate based on readings from the CGM (continuous glucose monitor). A more advanced SmartGuard algorithm was released in 2020 (2023 in the United States) as part of the 780G. It can deliver automated boluses and has an optional glucose target of 100 mg/dl. The 670G used Medtronic's own proprietary algorithm. For the 780G, the SmartGuard algorithm was adapted from an algorithm licensed by Medtronic in 2015 from medical technology company DreaMed. DreaMed, based at the Schneider Children's Medical Center of Israel in Tel Aviv, created the algorithm in the late 2000s. At first called MD-Logic Artificial Pancreas, then GlucoSitter, it used machine learning to increase the patient's time in the 80–120 mg/dl range. DreaMed's algorithm performed well in clinical trials as of 2011. Initially, the pump was compatible only with MiniMed's own CGMs, the Guardian 3 and Guardian 4. In 2025, MiniMed introduced two new CGMs for the 780G, the Simplera Sync and the Instinct, made by Abbott Laboratories.
Histoire et dictionnaire de Paris [History and dictionary of Paris] (in French). Paris: Éditions Robert-Laffont. Auguste, Jal (1872). Dictionnaire critique de biographie et d'histoire [Critical Dictionary of Biography and History] (in French). Paris: Éditions Plon. Piot, Eugène (1873). État civil de quelques artistes français [Marital status of some French artists] (in French). Paris: Librairie Pagnerre.
It uses a wide range of organic material for food; in animals, its versatility enables it to infect damaged tissues or those with reduced immunity. The symptoms of such infections are generalized inflammation and sepsis. If such colonizations occur in critical body organs, such as the lungs, urinary tract, and kidneys, the results can be fatal. Because it thrives on moist surfaces, this bacterium is also found on and in soap and medical equipment, including catheters, causing cross-infections in hospitals and clinics. It is also able to decompose hydrocarbons and has been used to break down tarballs and oil from oil spills. P. aeruginosa is not extremely virulent in comparison with other major species of pathogenic bacteria such as Gram-positive Staphylococcus aureus and Streptococcus pyogenes , although P. aeruginosa is capable of extensive colonization and can aggregate into enduring biofilms. Its genome includes numerous genes for transcriptional regulation and antibiotic resistance, such as efflux systems and beta-lactamases, which contribute to its adaptability and pathogenicity in human hosts. P. aeruginosa produces a characteristic sweet, grape-like odor due to its synthesis of 2-aminoacetophenone.
) to identify patterns such as sudden jumps or drops in stream power, these features can help identify locations where the local terrain controls the flow or widens out as well as areas prone to erosion.
Almost all saffron grows in a belt stretching from Spain in the west to India in the east. Iran is responsible for around 90% of global production, and in 2024 was the largest producer, followed by Afghanistan. Saffron is cultivated in 26 of Afghanistan's 34 provinces, with most production concentrated in Herat. Greece is the third largest producer, followed by Spain, which was once the largest producer in the 19th century. Other producers include the United Arab Emirates, the Indian subcontinent (particularly Kashmir), and Morocco.
Sources: en.wikipedia.org
From this view, the Soviet Union was so weak and devastated after the end of the Second World War as to be unable to pose any serious threat to the US, which emerged after 1945 as the sole world power not economically devastated by the war, and also as the sole possessor of the atomic bomb until 1949. Gaddis, however, argues that the conflict was less the lone fault of one side or the other and more the result of a plethora of conflicting interests and misperceptions between the two superpowers, propelled by domestic politics and bureaucratic inertia. While Gaddis does not hold either side as entirely responsible for the onset of the conflict, he argues that the Soviets should be held at least slightly more accountable for the problems. According to Gaddis, Stalin was in a much better position to compromise than his Western counterparts, given his much broader power within his own regime than Truman, who had to contend with Congress and was often undermined by vociferous political opposition at home. Gaddis further recognises the role of personal politics, combined with Truman's inexperience in foreign affairs and "abrasive personality", in the breakdown of the Grand Alliance. Personal politics played a role in how Truman dealt with Stalin, and in the Russians seeing Roosevelt's post-war plans as deserted.
== Publications == Tongraar, A.; Liedl, K. R.; Rode, Bernd M. (1997);"Solvation of Ca2+ In Water Studied By Born-Oppenheimer Ab-Initio QM/MM Dynamics"; J. Phys. Chem. A 1997, 101(35), p. 6299-6309,DOI: 10.1021/jp970963t. Rode, Bernd M.; Schwenk, Christian F., Tongraar, Anan (2004); "Structure and Dynamics of Hydrated Ions - New Insights through Quantum Cechanical Simulation"; J. Mol. Liq. 2004, 110(1-3), pp. 105–122. DOI: 10.1016/j.molliq.2003.09.016. Hofer, Thomas; Pribil, Andreas; Randolf, Bernhard; Rode, Bernd M. (2005); "Structure and dynamics of solvated Sn(II) in aqueous solution - an ab initio QM/MM MD approach", J. Am. Chem. Soc. 2005, 127(41), p. 14231-14238. DOI:10.1021/ja052700f. Rode, Bernd M.; Schwenk, Christian; Hofer, Thomas; Randolf, Bernhard (2005); "Coordination and ligand exchange dynamics of solvated metal ions"; Coord. Chem. Rev. 2005, 249(24), pp. 2993-–3006. DOI: doi:10.1016/j.ccr.2005.03.032. Rode, Bernd M.; Hofer, Thomas (2006); "How to Access Structure and Dynamics of Solutions: The Capabilities of Computational Methods", Pure Appl. Chem. 2006, 78(3), pp. 525–539. DOI: 10.1351/pac200678030525. Rode, Bernd M.; Hofer, Thomas; Randolf, Bernhard; Schwenk, Christian; Xenides, Demetrios; Vchirawongkwin, Viwat(2006); "Ab initio Quantum Mechanical Charge Field (QMCF) Molecular Dynamics - A QM/MM - MD Procedure for Accurate Simulations of Ions and Complexes"; Theor. Chem. Acc. 2006, 115(2-3), pp. 77–85. DOI: 10.1007/s00214-005-0049-1. Hofer, Thomas S.; Randolf, Bernhard R.; Rode, Bernd M.
=== Biomedical === Nanoscale particles are used in biomedical applications as drug carriers or imaging contrast agents in microscopy. Anisotropic nanoparticles are a good candidate in biomolecular detection. Moreover, nanoparticles for nucleic acid delivery offer an unprecedented opportunity to overcome some drawbacks related to the delivery, owing to their tunability with diverse physico-chemical properties, they can readily be functionalized with any type of biomolecules/moieties for selective targeting. Using nanoparticles in cancer treatment is being extensively researched. Certain characteristics of the tumor microenvironment, including leaky vasculature and poor lymphatic drainage, lead to the accumulation of NPs in the tumor. This is known as the enhanced permeability and retention (EPR) effect, and is a type of passive targeting. Additionally, ligands that bind to certain expressed or over-expressed receptors in the tumor microenvironment can be conjugated to the surface of nanoparticles to actively target the tumor. The accumulation of nanoparticles in the tumor can reduce adverse side effects, which is a major drawback of chemotherapy. In drug delivery, the acidic pH of the tumor microenvironment is often exploited to increase the release of the drug from pH-sensitive materials. Additionally, some NPs can generate heat under laser irradiation (photothermal therapy) or alternating magnetic field (magnetic hyperthermia), which can both kill cancer cells, and release drugs loaded in the nanoparticle.
== High-molecular-weight DNA extraction method == In this method, plant nuclei are isolated by physically grinding tissues and reconstituting the intact nuclei in a unique Nuclear Isolation Buffer (NIB). The plastid DNAs are released from organelles and eliminated with an osmotic buffer by washing and centrifugation. The purified nuclei are then lysed and further cleaned by organic extraction, and the genomic DNA is precipitated with a high concentration of CTAB. The highly pure, high molecular weight gDNA is extracted from the nuclei, dissolved in a high pH buffer, allowing for stable long-term storage.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.